Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans.
Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans.
复制标题
DOI：
10.1084/jem.20220732
复制
发表时间：
2022-08-01
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
Cho等人描述了与mRNA疫苗相比，单剂量Ad26.COV2.S疫苗后的抗体免疫应答。他们发现Ad26.COV2.S疫苗接种产生较少的记忆B细胞，但其效力和广度与mRNA疫苗接种后的结果相当。单剂量Ad.26.COV.2（Janssen）疫苗产生的中和抗体水平较低，与两种可用的mRNA疫苗相比，在预防感染方面显示出更有限的效力。此外，Ad.26.COV.2在Omicron激增期间对严重疾病的保护效果较差。在这里，我们检查了记忆B细胞对单剂量Ad.26.COV.2疫苗接种的反应。与mRNA疫苗相比，Ad.26.COV.2受体在接种后1.5或6个月具有显著较低的RBD特异性记忆B细胞数量。尽管数量较少，但记忆B细胞应答的总体质量似乎相似，因此两种疫苗类型引发的记忆抗体显示出对SARS-CoV-2武汉-胡-1、Delta和Omicron BA.1变体的相当的中和效力。这些数据有助于解释为什么用mRNA疫苗接种Ad.26.COV.2疫苗接种者是有效的，以及为什么Ad26.COV2.S疫苗可以在Omicron激增期间保持一定的保护效力。
Cho et al. describe the antibody immune response after a single dose of the Ad26.COV2.S vaccine compared with mRNA vaccines. They find that Ad26.COV2.S vaccination produces fewer memory B cells but with a potency and breadth comparable to those found after mRNA vaccination. The single-dose Ad.26.COV.2 (Janssen) vaccine elicits lower levels of neutralizing antibodies and shows more limited efficacy in protection against infection than either of the two available mRNA vaccines. In addition, Ad.26.COV.2 has been less effective in protection against severe disease during the Omicron surge. Here, we examined the memory B cell response to single-dose Ad.26.COV.2 vaccination. Compared with mRNA vaccines, Ad.26.COV.2 recipients had significantly lower numbers of RBD-specific memory B cells 1.5 or 6 mo after vaccination. Despite the lower numbers, the overall quality of the memory B cell responses appears to be similar, such that memory antibodies elicited by both vaccine types show comparable neutralizing potency against SARS-CoV-2 Wuhan-Hu-1, Delta, and Omicron BA.1 variants. The data help explain why boosting Ad.26.COV.2 vaccine recipients with mRNA vaccines is effective and why the Ad26.COV2.S vaccine can maintain some protective efficacy against severe disease during the Omicron surge.
登录
查看更多内容
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
影响因子：
64.8
作者：
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者：
Nussenzweig MC
影响因子：
82.9
作者：
Amanat F;Stadlbauer D;Strohmeier S;Nguyen THO;Chromikova V;McMahon M;Jiang K;Arunkumar GA;Jurczyszak D;Polanco J;Bermudez-Gonzalez M;Kleiner G;Aydillo T;Miorin L;Fierer DS;Lugo LA;Kojic EM;Stoever J;Liu STH;Cunningham-Rundles C;Felgner PL;Moran T;García-Sastre A;Caplivski D;Cheng AC;Kedzierska K;Vapalahti O;Hepojoki JM;Simon V;Krammer F
通讯作者：
Krammer F
mRNA疫苗会诱导SARS-COV-2和关注的变体诱导耐用的免疫记忆。
DOI：
10.1126/science.abm0829
发表时间：
2021-12-03
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
通讯作者：
--
DOI：
10.1016/s0140-6736(22)00007-1
发表时间：
2022-03-19
期刊：
Lancet (London, England)
影响因子：
--
作者：
Bekker LG;Garrett N;Goga A;Fairall L;Reddy T;Yende-Zuma N;Kassanjee R;Collie S;Sanne I;Boulle A;Seocharan I;Engelbrecht I;Davies MA;Champion J;Chen T;Bennett S;Mametja S;Semenya M;Moultrie H;de Oliveira T;Lessells RJ;Cohen C;Jassat W;Groome M;Von Gottberg A;Le Roux E;Khuto K;Barouch D;Mahomed H;Wolmarans M;Rousseau P;Bradshaw D;Mulder M;Opie J;Louw V;Jacobson B;Rowji P;Peter JG;Takalani A;Odhiambo J;Mayat F;Takuva S;Corey L;Gray GE;Sisonke Protocol Team;Sisonke Study Team
通讯作者：
Sisonke Study Team